Table 2. FOLFIRINOX Treated Patients.
| Pre-FOLFIRINOX Treatment (n = 40) | Post-FOLFIRINOX Treatment (n = 40) | P | |
|---|---|---|---|
| CA 19.9, median (range)1 | 169 (1–4754) | 0.17 (0.01–9.81) | <0.001 |
| CA 19.9 > 40 U1 | 26 (70.3%) | 11 (28.9%) | <0.001 |
| Tumor diameter at CT, median (range), cm | 3.6 (0–6.0) | 2.1 (0–5.4) | <0.001 |
| Gastrointestinal consensus group | LAPC = 25 (62.5%) | Complete = 6 (15%) | |
| Borderline = 15 (37.5%) | Partial = 30 (75%) | ||
| Stable = 4 (10%) | |||
| Progression = 0 | |||
| Blinded review by senior pancreatic surgeon (A.L.W.) | Resectable—0 | Resectable—12 (30%) | |
| Borderline—14 (35%) | Borderline—9 (22%) | ||
| LA—26 (65%) | LA—19 (48%) |
LAPC indicates locally advanced pancreatic cancer.